MDGL — MADRIGAL PHARMACEUTICALS, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1157601 ·
Last close
$544.51
Market Cap
$12.55B
52W High
$569.44
52W Low
$445.20
ADV30
378,126
Next earnings
2026-07-30
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 311,337,000 | 284,490,000 | -92,723,000 | -94,391,000 | 1,227,327,000 | 227,033,000 | 683,873,000 |
| Dec 2025 | 321,083,000 | 296,635,000 | -59,609,000 | -58,575,000 | 1,259,589,000 | 198,693,000 | 656,900,000 |
| Sep 2025 | 287,268,000 | 269,146,000 | -113,975,000 | -114,190,000 | 1,362,457,000 | 295,694,000 | 736,725,000 |
| Jun 2025 | 212,802,000 | 203,737,000 | -47,202,000 | -42,281,000 | 1,015,381,000 | 186,193,000 | 319,403,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-268,097,000
Investing CF
$60,633,000
Financing CF
$249,673,000
CapEx
$-4,823,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-12.80
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-2,184,857,000
Inventory
$112,070,000
Receivables
$187,356,000
ST Investments
$585,738,000
EBIT TTM
$-282,606,000
Pretax Income TTM
$-309,437,000
Interest Exp TTM
$26,831,000
Analysts
12
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,132,489,984
EBITDA
$-311,996,000
Free Cash Flow
$-156,403,504
Enterprise Value
$12,061,832,192
Total Cash
$812,771,008
Total Debt
$347,311,008
Shares Out
23,055,659
Trailing EPS
$-13.48
Book Value
$23.59
ROE
-49.3%
ROA
-17.6%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 958,403,000 | -300,097,000 | -288,284,000 | 1,259,589,000 | 656,900,000 | — | -189,553,000 |
| Dec 2024 | 180,133,000 | -497,875,000 | -465,892,000 | 1,042,247,000 | 287,864,000 | — | -455,572,000 |
| Dec 2023 | 0 | -380,496,000 | -373,630,000 | 640,547,000 | 235,214,000 | — | -324,230,000 |
| Dec 2022 | 0 | -293,571,000 | -295,350,000 | 362,572,000 | 165,183,000 | — | -224,857,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$12.38
Max Pain — expiry 2026-12-18
max pain strike: $500.00 · spot: $544.51 · call oi: 2,588 · put oi: 1,276
Expected Move to 2026-12-18:
±$235.75
(43.30%) —
implied range
$308.76 –
$780.26
· ATM straddle on $540.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ELAN | Elanco Animal Health Inc | $12.44B | $24.91 | — |
| AXSM | Axsome Therapeutics, Inc. | $12.40B | $241.00 | — |
| AAVXF | Abivax S.A. | $12.12B | $139.00 | — |
| ARWR | ARROWHEAD PHARMACEUTICALS, INC. | $12.06B | $85.60 | — |
| BMRN | BIOMARIN PHARMACEUTICAL INC | $11.47B | $59.33 | — |
News headlines (Yahoo Finance, 1h cache)
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
2026-07-21 20:05 · Yahoo
Madrigal Pharmaceuticals to Release Second-Quarter 2026 Financial Results and Host Webcast on July 30, 2026
2026-07-16 12:00 · Yahoo
MDGL Stock In Focus — Retail Traders Buzz Over M&A Speculation And Fresh Patents For Liver Drug
2026-07-13 23:47 · Yahoo
Madrigal Pharmaceuticals Announces Three New Resmetirom Patents, Strengthening IP Portfolio
2026-07-13 12:00 · Yahoo
3 Under-the-Radar Stocks to Buy and Hold
2026-07-10 18:50 · Yahoo
BofA lowers its Price Target on Madrigal Pharmaceuticals, Inc. (MDGL)
2026-07-08 19:20 · Yahoo
Ribo and Madrigal Reach First Major Milestone in Advancing Novel siRNA Therapies for MASH
2026-07-02 01:29 · Yahoo
3 late-stage MASH drugs that could rival Rezdiffra
2026-06-29 09:00 · Yahoo
3 Under-the-Radar Stocks to Buy and Hold for a Decade
2026-06-16 07:50 · Yahoo
The Bull Case For Madrigal Pharmaceuticals (MDGL) Could Change Following New Rezdiffra Cardiometabolic Data Release
2026-06-09 06:14 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.